Please assess the completion status of the following clinical trial:

Trial Title: S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed non-small cell lung cancer~  * Stage IA (longest tumor diameter 2-3 cm) or stage IB disease~* Must have undergone preoperative CT scan of the chest (including the entire liver and adrenals) with IV contrast AND a whole body PET scan or a combined PET/CT scan with no evidence of N1, N2, N3, or M1 disease within 42 days prior to surgery~* A whole body PET scan or a combined PET/CT must be performed within 84 days~  * Any finding on PET scan that clinically suggests N1, N2, N3, or M1 disease must have been cleared by further evaluation, including, but not limited to, any of the following:~    * Ultrasonography, X-ray radiology, magnetic resonance imaging, or nuclear medicine imaging~* Completely resected (R0) disease by lobectomy, bilobectomy, or pneumonectomy performed by open thoracotomy or video-assisted thoracoscopic surgery within the past 35 days~  * Completely excised primary lesion with negative gross and microscopic margins~ * At least two mediastinal lymph node stations sampled~* Must have tumor tissue available from the surgical resection specimen AND agree to have treatment assignment determined by a gene expression analysis performed on that tissue~PATIENT CHARACTERISTICS:~* Zubrod performance status 0-1~* ANC ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Hemoglobin ≥ 10 mg/dL~* Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)~* AST and ALT ≤ 1.5 times ULN~* Serum creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No other prior malignancy except for the following:~  * Adequately treated basal cell or squamous cell skin cancer~ * In situ cervical cancer~ * Adequately treated stage I-II cancer from which the patient is currently in complete remission~ * Any other cancer from which the patient has been disease-free for 5 years~* Willing to provide prior smoking history~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior systemic chemotherapy or biologic therapy for lung cancer~* No prior thoracic radiation therapy (RT) (including RT to the chest wall)~* No other concurrent investigational agents, chemotherapeutic agents, RT, or hormonal therapy~  * Steroids administered for antiemesis, adrenal failure, or septic shock OR hormones administered for non-disease-related conditions (e.g., insulin for diabetes) allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm II (Type: EXPERIMENTAL): Beginning within 84 days after surgery, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and cisplatin IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).